Hemodynamic effects of continuous urodilatin infusion: a dose-finding study. (Q54123124)

25 May 2018

title

Hemodynamic effects of continuous urodilatin infusion: a dose-finding study. (English)

1 reference

25 May 2018

1 reference

Dorner GT

1

1 reference

25 May 2018

Selenko N

2

1 reference

25 May 2018

Kral T

3

1 reference

25 May 2018

Schmetterer L

4

1 reference

25 May 2018

Eichler HG

5

1 reference

25 May 2018

Wolzt M

6

1 reference

25 May 2018

language of work or name

English

0 references

publication date

1 September 1998

1 reference

25 May 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

25 May 2018

volume

64

1 reference

25 May 2018

issue

3

1 reference

25 May 2018

page(s)

322-330

1 reference

25 May 2018

Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Doppler ultrasonic measurement of cardiac output: reproducibility and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Comparison of non-invasive methods for the assessment of haemodynamic drug effects in healthy male and female volunteers: sex differences in cardiovascular responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Urodilatin: a new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Urodilatin: a newly described member of the ANP family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Urodilatin (ularitide, INN): a renal natriuretic peptide. Molecular biology and clinical importance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Type A natriuretic peptides exhibit different bronchoprotective effects in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Treatment of acute postoperative renal failure after liver and heart transplantation by urodilatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Urodilatin: a new approach for the treatment of therapy-resistant acute renal failure after liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Systolic time intervals reconsidered. Reevaluation of the preejection period: absence of relation to heart rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Systolic time intervals in heart failure in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Simplified measurement of p-aminohippurate and other arylamines in plasma and urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Urodilatin (INN: Ularitide) Ein neues Peptid in der Intensivbehandlung des akuten Nierenversagens nach Lebertransplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Haemodynamic and renal effects of urodilatin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Effects of urodilatin in the rat kidney: comparison with ANF and interaction with vasoactive substances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990181-3

10.1016/S0009-9236(98)90181-3

7 January 2021

Identifiers

DOI

1 reference

25 May 2018

PubMed ID

9757156

1 reference

25 May 2018